Rodney Davis continues to take thousands of dollars from big drug companies, over $200,000 during his time in Congress, and voted against a bipartisan effort to lower RX prices. He even voted to give those drug companies more than $40 billion in tax handouts.

**MapLight: Davis Accepted More Than $200,000 From Pharmaceutical Company PACs.** According to a MapLight search on July 22, 2020, Davis $203,700.00 from various pharmaceutical companies corporate PACs. [MapLight, accessed 7/22/20]

**Davis Voted Against The Elijah E. Cummings Lower Drug Costs Now Act, Which Would Allow The Federal Government To Negotiate Lower Drug Prices.** In December 2019, Perry voted against: “Passage of the bill, as amended, that would allow the Health and Human Services Department to negotiate prices for certain drugs under Medicare programs and would make a number of modifications to Medicare programs related to drug costs and plan benefits. Specifically, the bill would establish a fair price negotiation program in which HHS would enter into agreements with drug manufacturers negotiate maximum fair prices for certain drugs.” The motion passed by a vote of 230-192. [HR 3, Vote #682, 12/12/19; CQ, 12/12/19]

*The Bill Would Cap Seniors’ Out-Of-Pocket Costs For Prescription Drugs At $2,000 Per Year.* “It would also cap seniors’ out-of-pocket prescription drug costs at $2,000 a year. And it would require drug companies that have raised their prices above the inflation rate since 2016 to either lower their prices or rebate the portion back to the U.S. Treasury.” [Washington Post, 9/19/19]

**CBO: H.R. 3’s Negotiation Provision Would Reduce Drug Prices By 55 Percent.** “CBO then estimated net spending for drugs with the international prices selected for negotiation under title I [of H.R. 3]. CBO estimates that reducing prices to 114 percent of the AIM price, on average, would reduce—by nearly 55 percent—the prices for the first group of drugs subject to negotiation.” [Congressional Budget Office, 10/11/19]

**Davis Voted For Final Passage Of The Tax Cuts And Jobs Act.** [HR 1, Vote #699, 12/20/17; CQ Floor Votes, 12/20/17]

**Politico: Repatriation Provision In Tax Bill Was A “Major Victory For Pharma Manufacturers.”** “The bill, H.R. 1 (115), lowers the corporate tax rate and would offer a one-time reduction on profits U.S.-based multinational companies earn and keep abroad. The repatriation provision is seen as a major victory for pharma manufacturers who store boatloads of cash in countries where tax rates are lower.” [Politico, 12/4/17]

**Pharmaceutical Companies Were “One Of The Biggest Beneficiaries” Of The Provision, And Were Seen As Likely To Return Money To Their Shareholders, Rather Than Invest In Research And Innovation.** “U.S. drugmakers will be one of the biggest beneficiaries of the repatriation portion of the bill. They’ve been sitting on billions of dollars in overseas earnings and can now bring home that cash at a reduced rate. While the tax bill has been promoted by Republicans as a job creator, the reality is that drug companies are more likely to return the money to shareholders, or use it to make acquisitions.” [Bloomberg, 12/20/17]

**Tax Bill Was Estimated To Save Top Five Pharmaceutical Companies $42.7 Billion.** “The tax proposal supported by President Donald Trump and congressional Republicans would give five top pharmaceutical corporations a $42.7 billion tax break.” [Public Citizen and ITEP, 11/20/17]